Chief Medical Director Kari Syrjänen will retire from Biohit Oyj

Helsinki, FINLAND

Biohit Oyj 31.12.2018 12:00

Biohit’s management team member Chief Medical Director Kari Syrjänen will retire as planned 31st of December 2018. Kari Syrjänen has been employed by Biohit since 2013.

”I would like to thank Kari for the excellent work during these years”, says Semi Korpela, President and CEO of Biohit.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861


Biohit Oyj in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission ‘Innovating for Health’ means that we provide innovative products and services to promote research and early diagnostics. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares (BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare.